Senti Biosciences Holdings, Inc. (SNTI)

Market Cap	30.52M -64.3%
Revenue (ttm)	38,000
Net Income	-51.55M
EPS	-1.86
Shares Out	31.14M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	179,154
Open	0.8864
Previous Close	0.8804
Day's Range	0.8629 - 0.9800
52-Week Range	0.7702 - 3.8840
Beta	2.10
Analysts	Strong Buy
Price Target	11.25 (+1,047.96%)
Earnings Date	May 14, 2026

About SNTI

Senti Biosciences Holdings, Inc., a clinical stage biotechnology company, develops cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The company’s lead product candidates utilize off-the-shelf healthy adult donor derived natural killer (NK) cells to create CAR-NK cells outfitted with gene circuit technologies in various oncology indications with unmet need. It offers SENTI-202, a logic gated off-the-shelf CAR-NK cell therapy for the treatment of blood cancers and relapsed...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2016
• Employees: 39
• Stock Exchange: NASDAQ
• Ticker Symbol: SNTI
• Website: https://www.sentibio.com

Analyst Summary

According to 4 analysts, the average rating for SNTI stock is "Strong Buy." The 12-month stock price target is $11.25, which is an increase of 1,047.96% from the latest price.

Price Target

$11.25

(1,047.96% upside)

Analyst Consensus: Strong Buy